Skip to main content
SpringerLink
Log in

Radiopharmaceuticals

  • Chapter
  • First Online:
Drug Management of Prostate Cancer

  • 1241 Accesses

Abstract

Bone-targeted radiopharmaceuticals have an established role as safe and effective agents for the treatment of men with bone-metastatic castration-resistant prostate cancer (CRPC). Three FDA approved radiopharmaceuticals are available for use by clinicians including 153samarium-EDTMP, 89strontium chloride, and 32phosphorus. Data from placebo-controlled randomized trials support the palliative use of these compounds but no consensus currently exists regarding how these compounds should be sequenced with other agents known to be active in the CRPC patient. Multiple factors, including market forces, have limited current use. Newer bone-targeted isotopic therapies are currently under development and large phase III multinational placebo-controlled trials in bone-metastatic CRPC patients are currently being planned for 223radium. Combinations of radiopharmaceuticals and chemotherapy have yielded promising survival results in small randomized studies, but confirmation of survival benefit in larger studies has yet to occur. Various combinations of radiopharmaceuticals and chemotherapy are currently under active investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol Radium Ther 1950;64:559–75.

    PubMed  CAS  Google Scholar 

  2. Kaplan E, Fels, IG, Kotlowski BR, et al. Therapy of carcinoma of the prostate metastatic to bone with P32 labeled condensed phosphate. J Nucl Med 1960;1:1–13.

    Google Scholar 

  3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.

    Article  PubMed  Google Scholar 

  4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.

    Article  PubMed  CAS  Google Scholar 

  5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.

    Article  PubMed  CAS  Google Scholar 

  6. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232–41.

    Article  PubMed  CAS  Google Scholar 

  7. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–68.

    Article  PubMed  CAS  Google Scholar 

  8. Licciardone JC. The epidemiology and medical management of low back pain during ambulatory medical care visits in the United States. Osteopath Med Prim Care 2008;2:11.

    Article  PubMed  Google Scholar 

  9. Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer – Genitourinary Group Study 30853. Cancer 1993;72(12 Suppl):3793–8.

    Article  PubMed  CAS  Google Scholar 

  10. Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933–41.

    Article  PubMed  CAS  Google Scholar 

  11. Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005;5:543–55.

    Article  PubMed  CAS  Google Scholar 

  12. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232–7; erratum in: J Clin Oncol 2004;22:3434.

    Article  PubMed  Google Scholar 

  13. Beer TM, Tangen CM, Bland LB, et al. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. J Urol 2004;172:2213–7; erratum in: J Urol 2005;174:1156.

    Article  PubMed  Google Scholar 

  14. Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 1977;266:653–5.

    Article  PubMed  CAS  Google Scholar 

  15. Ben-Josef E, Maughan RL, Vasan S, Porter AT. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun 1995;16:452–6.

    Article  PubMed  CAS  Google Scholar 

  16. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987;28:495–504.

    PubMed  Google Scholar 

  17. Vinjamuri S, Ray S. Phosphorus-32: The forgotten radiopharmaceutical? Nucl Med Commun 2008;29:95–7.

    Article  PubMed  Google Scholar 

  18. Henriksen G, Breistøl K, Bruland ØS, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120–5.

    PubMed  CAS  Google Scholar 

  19. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I Study of Samarium-153 Lexidronam (153Sm-EDTMP) with Docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009;27:2436–42.

    Article  PubMed  CAS  Google Scholar 

  20. Fizazi P, Beuzeboc J, Lumbroso, et al. A prospective Phase II trial of consolidation Docetaxel and Samarium-153 in patients with bone metastases from castration resistant prostate cancer. J Clin Oncol 2009;27:2429–35.

    Google Scholar 

  21. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized Phase II trial. Lancet 2001;357:336–41; erratum in: Lancet 2001;357:1210.

    Article  PubMed  CAS  Google Scholar 

  22. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79–86.

    PubMed  CAS  Google Scholar 

  23. Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999;52:101–9; erratum in: Radiother Oncol 1999;53:167; Leer J [corrected to Leer JW]; van Mierlo T [corrected to van Mierlo I].

    Article  PubMed  CAS  Google Scholar 

  24. Wu JS, Monk G, Clark T, et al. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol) 2006;18:539–44.

    Article  CAS  Google Scholar 

  25. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation of Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519–26.

    Article  PubMed  CAS  Google Scholar 

  26. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33–40.

    Article  PubMed  CAS  Google Scholar 

  27. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805–13.

    Article  PubMed  CAS  Google Scholar 

  28. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27:954–8.

    Article  PubMed  CAS  Google Scholar 

  29. Buchali K, Correns HJ, Schuerer M, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 1988;14:349–51.

    PubMed  CAS  Google Scholar 

  30. Kasalický J, Krajská V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998;25:1362–7.

    Article  PubMed  Google Scholar 

  31. Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 1997;24:1210–4.

    Article  PubMed  CAS  Google Scholar 

  32. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574–81.

    PubMed  CAS  Google Scholar 

  33. Sartor O, Reid RH, Hoskin PJ, et al. Quadramet 424Sm10/11 Study Group. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940–5.

    Article  PubMed  Google Scholar 

  34. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007;109:637–43.

    Article  PubMed  CAS  Google Scholar 

  35. Higano CS, Quick DP, Bushnell D, Sartor O. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. Clin Genitourin Cancer 2008;6:40–5.

    Article  PubMed  CAS  Google Scholar 

  36. Nilsson S, Larsen RH, Fossa SD, et al. First Clinical Experience with α emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451–59.

    Article  PubMed  CAS  Google Scholar 

  37. Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587–94.

    Article  PubMed  CAS  Google Scholar 

  38. Baczyk M, Czepczyński R, Milecki P, et al. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 2007;28:245–50.

    Article  PubMed  Google Scholar 

  39. Nair N. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 1999;40:256–61.

    PubMed  CAS  Google Scholar 

  40. Liepe K, Korzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153 Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007;28:623–30.

    Article  PubMed  CAS  Google Scholar 

  41. Berenson A. Market Forces Cited in Lymphoma Drugs’ Disuse. New York Times, July 14, 2007 (http://www.nytimes.com/2007/07/14/health/14lymphoma.html, referenced 1/5/09).

  42. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005;23:7904–10.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Urology, Tulane Medical School, New Orleans, LA, USA

    Oliver Sartor

Authors
  1. Oliver Sartor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Damerla R. Venugopal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oliver Sartor .

Editor information

Editors and Affiliations

  1. Medical Oncology Branch, NIH National Cancer Institute, Rockville Pike 9000, Bethesda, 20892, Maryland, USA

    William D. Figg

  2. Medical Oncology Branch, NIH National Cancer Institute, Rockville Pike 9000, Bethesda, 20892, Maryland, USA

    Cindy H. Chau

  3. School of Medicine, Dept. Urology, University of California, San Francisco, Divisadero Street 1600, San Francisco, 94115, California, USA

    Eric J. Small

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sartor, O., Venugopal, D.R. (2010). Radiopharmaceuticals. In: Figg, W., Chau, C., Small, E. (eds) Drug Management of Prostate Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-829-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-829-4_23

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-831-7

  • Online ISBN: 978-1-60327-829-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation